This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Pinto Slottow, T. L. Articles by Waksman, R. Search for Related Content PubMed PubMed Citation Articles by Pinto Slottow, T. L. Articles by Waksman, R. Related Collections Catheter-based coronary interventions: stents Chronic ischemic heart disease

(Circulation. 2008;117:1603-1608.)
© 2008 American Heart Association, Inc.

New Drugs and Technologies

Overview of the 2007 Food and Drug Administration Circulatory System Devices Panel Meeting on the Endeavor Zotarolimus-Eluting Coronary Stent

Tina L. Pinto Slottow, MD; Ron Waksman, MD

From the Division of Cardiology, Washington Hospital Center, Washington, DC.

Correspondence to Ron Waksman, MD, Washington Hospital Center, 110 Irving St NW, Ste 4B-1, Washington, DC 20010. E-mail ron.waksman@medstar.net

Key Words: drug-eluting stents • heart disease • atherosclerosis

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
Initial trials comparing stenting with balloon angioplasty demonstrated improved angiographic and clinical outcomes with the former.^1–3 The main clinical problem with bare metal stents (BMS) became the development of in-stent restenosis.^4–6 Early data suggested that drug-eluting stents (DES) could mitigate, if not abolish, this problem.^7–9 Since the approval of DES, these devices have become the predominant stents used in percutaneous coronary interventions, regardless of indication. As of September 2007, the Cypher sirolimus-eluting stent (SES) (Cordis Johnson & Johnson, Miami Lakes, Fla) had been deployed in >3 million patients worldwide,¹⁰ and the millionth Taxus paclitaxel-eluting stent (PES) (Boston Scientific, Natick, Mass) was implanted as of January 2005.¹¹ Over the past 2 years, numerous reports of very late stent thrombosis (ST) with first-generation DES have surfaced. This highly morbid complication and data suggesting that death and myocardial infarction (MI) may be more common with DES^12,13 have altered the focus of trials and registries working to determine optimal DES use.

There is a hope that second-generation DES will be less prone to ST as a result of differences in drug, stent design, and polymer. Medtronic, Inc (Minneapolis, Minn) presented safety and efficacy data to a public meeting of the US Food and Drug Administration (FDA) Circulatory System Devices Panel (CSDP) in October 2007 on its Endeavor zotarolimus-eluting stent (ZES), seeking approval for the indication of treating de novo native coronary lesions 27 mm with reference vessel diameters of 2.5 to 3.5 mm. The FDA asked the CSDP to determine whether the data presented . . . [Full Text of this Article]